These two companies have averaged annual gains of more than 50% over the past five years -- and they're still growing.
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting primary and secondary endpoints with strong efficacy and safety. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results